Posted in Antibodies, Assay Kits, Biology Cells, cDNA, Clia Kits, DNA Templates, DNA Testing, Elisa Kits, Enzymes, Equipments, Exosomes, Gels, Isotypes, Reagents, Recombinant Proteins, Ria Kits, RNA
The Relationship of Cholangiocarcinoma with Human Immunodeficiency Virus Cholangiopathy and Cytomegalovirus Infection
The human immunodeficiency virus (HIV) is a disease worldwide with the increasing number of cases globally. Initially, HIV colliaiopati was often observed among these patients but has become rare after three decades due to the availability of new care choices and strong antiretroviral drugs. As a result, the incident now suggests drug resistance or the development of the disease. The relationship between Cholaghiocarcinoma and HIV is still unclear. We report cases of patients with high-grade dysplasia from Choledochus ducts and uncontrolled diseases treated with strong antivirus agents and dilated bile tract.
Learning points: HIV Choligiopathy must be remembered in HIV-positive patients even if they receive combination (train) antiretroviral therapy; Endoscopy Retrograde Choliaiopancreatography can provide symptomatic assistance. After HIV Chorangiopathy is detected, follow-up for Cholangiocarcinoma is needed. Corrected infections can cause choliaiocarcinoma in HIV-positive patients.
The decrease in the incidence of acute rejection without increasing the incidence of cytomegalovirus (CMV) infection in recipients of kidney transplants that accept the anti-thymocyte globulin (RATG) rabbit without prophylactic CMV
Induction therapy with the anti-thymocyte globulin (RATG) rabbit in recipients of low-risk ktridal transplants (KTR) remains controversial, given the increased risk of cytomegalovirus (CMV) infection. This natural experiment compares the clinical results of 12 months in low-risk KTR without CMV prophylaxis (Jan / 3/13-Sep / 16/15) accepting without induction or a single dose of 3mg / kg. We use logistic regression to characterize the pending graft function (DGF), negative binomials to characterize the length of hospitalization of hospitals (LOS) and Cox regression to characterize acute rejection (AR), CMV infection, mistrident of grafting, death and readmission.
The recipient received 3mg / kg Ratg had a risk of 81% lower than AR (AHR 0.14 0.190.25, p <0.001) but there was no increase in hospital admission due to infection (0.911.21, p = 0.5). There is no relationship between 3 mg / kg infection / CMV disease (AHR 0.86 1,101.40, p = 0.5), even when analysis is grouped based on the positive CMV serostatatus (AHR 0.94 1.25 1.65, p = 0, 15) and negative (AHR 0.28 0.57 1.16, p = 0.1). There is no relationship between 3MG / kg Ratg and mortality (AHR 0.51 1,253.08, p = 0.6), loss of grafts (AHR 0.34 0.731.55, p = 0.4). Among the low-risk ktr that does not accept the pharmacological prophylaxis of CMV, induction of 3mg / kg Ratg is associated with a significant reduction in the incidence of AR without an increased risk of CMV infection, regardless of the pre-transplant receiver CMV serostatus.
Lesions such as Degos as a skin manifestation of Cytomegalovirus infection: rare and serious complications in patients with drug induced hypersensitivity syndrome
Cytomegalovirus causes a myriad of clinical features, potentially influencing any organ system, significantly increases morbidity and even mortality. Vascular endothelial cell infections by CyTomeGalovirus have been involved in the development of Vasculopathy, perhaps accounting for clinical relations between Cytomegalovirus and vascular thrombosis. Unlike the involvement of visceral organs, cytomegalovirus skin manifestations varies and are rarely explained. Papulosis of malignant atrophy, which is commonly known as a Degos disease, is an unusual arteriopathic ship with a patognomonic clinical appearance from the middle porcelain-white papules surrounded by erythema Telangiectatic.
Like the arterial occlusive process, Degos may be idiopathic or secondary to autoimmune disorders or viral infections. All in all, presentations such as Degos related to Cytomegalovirus have never been explained. This report illustrates cases where disseminated cytomegalovirus disease is developed 4 weeks after the emergence of hypersensitivity syndrome induced by drugs with skin lesions such as prominent degos. Our case highlights a rare example of lesions such as Degos that occur because of cytomegalovirus disease and emphasizes the importance of early recognition of skin eruption characteristics as a diagnostic instrument that leads to the management of this life-threatening infection.
Cytomegalovirus pancreatitis in immunocompetent patients
Cytomegalovirus (CMV) is a DNA virus whose double strand, which infects most of the adult population. In immunocompetent patients, usually asymptomatic or manifest as symptoms of mild flu and self-limit, while in immunocompromised patients, CMV can cause significant disease. Here we report cases of unusual CMV pancreatitis in the 75-year-old woman’s immunocompetent. Patients develop severe significant pancreatic necrosis that failed non-operative management, and ultimately underwent the Pancreatic Necrosectomy. Then, he developed three spontaneous gastric perforations.
The first two perforations were managed operatively, but after the third perforation family decided not to undergo other operations. The diagnosis of CMV pancreatitis is based on pancreatic histopathology and confirms with a rapid response to Ganciclovir. The patient immediately began at Ganciclovir Intravenous (IV) which resulted in clinical recovery and he remained without symptoms of more than one year post op. This is a rare case of CMV pancreatitis with gastric perforation in immunocompetent patients. The level of suspicion is high and the right maintenance is important for such a clinical scenario.
Microvascular and structural abnormalities extralesional in cytomegalovirus retinitis
To evaluate extraesional microvascular and structural changes from the macula using Optical Coherence Tomography Angiography (Octa) and Structural October in the Citomegalovirus Retinitis (CMVR). A CMVR patient observational study was conducted. Complete ophthalmic examination, serial color fundus fundus, structural October and Octa are carried out at the beginning and follow-up visits up to 12 months. The structural OCT was analyzed to evaluate the macular area inside, bordering and exceed CMVR lesions.
Plexus extraledional retina capillaries from maculas are evaluated with October angiography and compared to fellow eyes that are not affected. Thirteen eyes from 13 registered patients. On the basis, the macular area without CMVR lesions showed a decrease in ship density (VD) of both superficial (p = 0,0002) and inside (p <0.0001) the retinal capillary plexus in the eye with CMVR compared to the area of the macular not affected by fellow eyes that are not affected. The decrease in VD survives through the follow-up period of up to 12 months after adjusting the degree of vitreous fog.
TTC9B rabbit pAb |
E44H14293 |
EnoGene |
100ul |
EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
TTC9B rabbit pAb |
UB-GEN-10081 |
UpingBio |
100 ul |
EUR 200 |
TTC39B |
CSB-CL713348HU |
Cusabio |
10 μg plasmid + 200μl Glycerol |
Ask for price |
TTC39B |
MBS8561883-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
TTC39B |
MBS8561883-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
TTC39B |
MBS8561883-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
TTC39B |
MBS8561883-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
TTC39B siRNA |
20-abx905851 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
TTC39B siRNA |
20-abx938469 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
TTC39B siRNA |
20-abx938470 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
TTC39B Antibody |
E309527 |
EnoGene |
200ul |
EUR 275 |
Description: Available in various conjugation types. |
TTC39B Antibody |
1-CSB-PA713348LA01HU |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against TTC39B. Recognizes TTC39B from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:500-1:5000 |
TTC39B Antibody |
MBS7113986-005mL |
MyBiosource |
0.05mL |
EUR 190 |
TTC39B Antibody |
MBS7113986-01mL |
MyBiosource |
0.1mL |
EUR 270 |
TTC39B Antibody |
MBS7113986-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1205 |
TTC39B Antibody |
MBS9632668-5x1mg |
MyBiosource |
5x1mg |
EUR 1545 |
TTC39B Antibody |
MBS9630285-01mL |
MyBiosource |
0.1mL |
EUR 260 |
TTC39B Antibody |
MBS9630285-02mL |
MyBiosource |
0.2mL |
EUR 305 |
TTC39B Antibody |
MBS9630285-5x02mL |
MyBiosource |
5x0.2mL |
EUR 1220 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) |
MBS645094-02mL |
MyBiosource |
0.2mL |
EUR 695 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) |
MBS645094-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2975 |
TTC39B siRNA (Rat) |
MBS8212375-15nmol |
MyBiosource |
15nmol |
EUR 405 |
TTC39B siRNA (Rat) |
MBS8212375-30nmol |
MyBiosource |
30nmol |
EUR 565 |
TTC39B siRNA (Rat) |
MBS8212375-5x30nmol |
MyBiosource |
5x30nmol |
EUR 2450 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (AP) |
MBS6359947-02mL |
MyBiosource |
0.2mL |
EUR 980 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (AP) |
MBS6359947-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (PE) |
MBS6359957-02mL |
MyBiosource |
0.2mL |
EUR 980 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (PE) |
MBS6359957-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (APC) |
MBS6359948-02mL |
MyBiosource |
0.2mL |
EUR 980 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (APC) |
MBS6359948-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
TTC39B cDNA Clone |
MBS1276545-001mgPlasmid02mLGlycerolStock |
MyBiosource |
0.01mgPlasmid+0.2mLGlycerol-Stock |
EUR 240 |
TTC39B cDNA Clone |
MBS1276545-5x001mgPlasmid5x02mLGlycerolStock |
MyBiosource |
5x0.01mgPlasmid+5x0.2mLGlycerol-Stock |
EUR 1030 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (FITC) |
MBS6359950-02mL |
MyBiosource |
0.2mL |
EUR 980 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (FITC) |
MBS6359950-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
TTC39B siRNA (Mouse) |
MBS8227271-15nmol |
MyBiosource |
15nmol |
EUR 405 |
TTC39B siRNA (Mouse) |
MBS8227271-30nmol |
MyBiosource |
30nmol |
EUR 565 |
TTC39B siRNA (Mouse) |
MBS8227271-5x30nmol |
MyBiosource |
5x30nmol |
EUR 2450 |
TTC39B siRNA (Human) |
MBS8213325-15nmol |
MyBiosource |
15nmol |
EUR 405 |
TTC39B siRNA (Human) |
MBS8213325-30nmol |
MyBiosource |
30nmol |
EUR 565 |
TTC39B siRNA (Human) |
MBS8213325-5x30nmol |
MyBiosource |
5x30nmol |
EUR 2450 |
Ttc39b (untagged) - Mouse tetratricopeptide repeat domain 39B (Ttc39b), (10ug) |
MC219732 |
Origene Technologies GmbH |
10 µg |
Ask for price |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (Biotin) |
MBS6359949-02mL |
MyBiosource |
0.2mL |
EUR 980 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (Biotin) |
MBS6359949-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
anti- TTC39B antibody |
FNab09086 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against TTC39B |
TTC33 Rabbit pAb |
E2612969 |
EnoGene |
100ul |
EUR 225 |
Description: Available in various conjugation types. |
TTC29 rabbit pAb |
E28PN4188 |
EnoGene |
100μl |
EUR 255 |
Description: Available in various conjugation types. |
TTC18 rabbit pAb |
E28PN4301 |
EnoGene |
100μl |
EUR 255 |
Description: Available in various conjugation types. |
TTC31 rabbit pAb |
E28PN4440 |
EnoGene |
100μl |
EUR 255 |
Description: Available in various conjugation types. |
TTC16 rabbit pAb |
E28PN4962 |
EnoGene |
100μl |
EUR 255 |
Description: Available in various conjugation types. |
TTC33 rabbit pAb |
E28PT6804 |
EnoGene |
100μl |
EUR 255 |
Description: Available in various conjugation types. |
TTC12 rabbit pAb |
E28PT7166 |
EnoGene |
100μl |
EUR 255 |
Description: Available in various conjugation types. |
TTC27 rabbit pAb |
E28PT7291 |
EnoGene |
100μl |
EUR 255 |
Description: Available in various conjugation types. |
TTC34 rabbit pAb |
E28PN3181 |
EnoGene |
100μl |
EUR 255 |
Description: Available in various conjugation types. |
TTC22 rabbit pAb |
E28PN3215 |
EnoGene |
100μl |
EUR 255 |
Description: Available in various conjugation types. |
TTC14 rabbit pAb |
E28PN3380 |
EnoGene |
100μl |
EUR 255 |
Description: Available in various conjugation types. |
TTC33 rabbit pAb |
E44H15357 |
EnoGene |
100ul |
EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
TTC12 rabbit pAb |
E44H15720 |
EnoGene |
100ul |
EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
TTC27 rabbit pAb |
E44H15845 |
EnoGene |
100ul |
EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
TTC14 rabbit pAb |
E44H12264 |
EnoGene |
100ul |
EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
TTC29 rabbit pAb |
E44H13072 |
EnoGene |
100ul |
EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
TTC18 rabbit pAb |
E44H13185 |
EnoGene |
100ul |
EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
TTC31 rabbit pAb |
E44H13324 |
EnoGene |
100ul |
EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
TTC16 rabbit pAb |
E44H13846 |
EnoGene |
100ul |
EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
TTC34 rabbit pAb |
E44H12065 |
EnoGene |
100ul |
EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
TTC22 rabbit pAb |
E44H12099 |
EnoGene |
100ul |
EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
TTC33 Rabbit pAb |
MBS8552513-01mL |
MyBiosource |
0.1mL |
EUR 305 |
TTC33 Rabbit pAb |
MBS8552513-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
TTC33 Rabbit pAb |
MBS8552513-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
TTC33 Rabbit pAb |
MBS8552513-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
TTC33 Rabbit pAb |
MBS8552513-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
TTC33 rabbit pAb |
UB-GEN-11262 |
UpingBio |
100 ul |
EUR 200 |
TTC12 rabbit pAb |
UB-GEN-11623 |
UpingBio |
100 ul |
EUR 200 |
TTC27 rabbit pAb |
UB-GEN-11747 |
UpingBio |
100 ul |
EUR 200 |
TTC34 rabbit pAb |
UB-GEN-7859 |
UpingBio |
100 ul |
EUR 200 |
TTC22 rabbit pAb |
UB-GEN-7892 |
UpingBio |
100 ul |
EUR 200 |
TTC14 rabbit pAb |
UB-GEN-8057 |
UpingBio |
100 ul |
EUR 200 |
TTC29 rabbit pAb |
UB-GEN-8862 |
UpingBio |
100 ul |
EUR 200 |
TTC18 rabbit pAb |
UB-GEN-8975 |
UpingBio |
100 ul |
EUR 200 |
TTC31 rabbit pAb |
UB-GEN-9113 |
UpingBio |
100 ul |
EUR 200 |
TTC16 rabbit pAb |
UB-GEN-9634 |
UpingBio |
100 ul |
EUR 200 |
TTC39B cloning plasmid |
CSB-CL713348HU-10ug |
Cusabio |
10ug |
EUR 333.6 |
|
Description: A cloning plasmid for the TTC39B gene. |
Ttc39b (Myc-DDK-tagged) - Mouse tetratricopeptide repeat domain 39B (Ttc39b) |
MR218431 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Ttc39b (GFP-tagged) - Mouse tetratricopeptide repeat domain 39B (Ttc39b), (10ug) |
MG218431 |
Origene Technologies GmbH |
10 µg |
Ask for price |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (MaxLight 405) |
MBS6359952-01mL |
MyBiosource |
0.1mL |
EUR 980 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (MaxLight 405) |
MBS6359952-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (MaxLight 490) |
MBS6359953-01mL |
MyBiosource |
0.1mL |
EUR 980 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (MaxLight 490) |
MBS6359953-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (MaxLight 550) |
MBS6359954-01mL |
MyBiosource |
0.1mL |
EUR 980 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (MaxLight 550) |
MBS6359954-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (MaxLight 650) |
MBS6359955-01mL |
MyBiosource |
0.1mL |
EUR 980 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (MaxLight 650) |
MBS6359955-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (MaxLight 750) |
MBS6359956-01mL |
MyBiosource |
0.1mL |
EUR 980 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (MaxLight 750) |
MBS6359956-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
TTC5 Rabbit pAb |
A13232-100ul |
Abclonal |
100 ul |
EUR 369.6 |
TTC5 Rabbit pAb |
A13232-200ul |
Abclonal |
200 ul |
EUR 550.8 |
TTC5 Rabbit pAb |
A13232-20ul |
Abclonal |
20 ul |
EUR 219.6 |
TTC5 Rabbit pAb |
A13232-50ul |
Abclonal |
50 ul |
EUR 267.6 |
TTC1 Rabbit pAb |
A8745-100ul |
Abclonal |
100 ul |
EUR 369.6 |
TTC1 Rabbit pAb |
A8745-200ul |
Abclonal |
200 ul |
EUR 550.8 |
TTC1 Rabbit pAb |
A8745-20ul |
Abclonal |
20 ul |
EUR 219.6 |
TTC1 Rabbit pAb |
A8745-50ul |
Abclonal |
50 ul |
EUR 267.6 |
TTC6 rabbit pAb |
E28PN4426 |
EnoGene |
100μl |
EUR 255 |
Description: Available in various conjugation types. |
TTC3 Rabbit pAb |
E2515734 |
EnoGene |
100ul |
EUR 225 |
Description: Available in various conjugation types. |
TTC5 rabbit pAb |
E28PN3935 |
EnoGene |
100μl |
EUR 255 |
Description: Available in various conjugation types. |
TTC8 Rabbit pAb |
A5129-100ul |
Abclonal |
100 ul |
EUR 369.6 |
TTC8 Rabbit pAb |
A5129-200ul |
Abclonal |
200 ul |
EUR 550.8 |
TTC8 Rabbit pAb |
A5129-20ul |
Abclonal |
20 ul |
Ask for price |
TTC8 Rabbit pAb |
A5129-50ul |
Abclonal |
50 ul |
Ask for price |
TTC3 Rabbit pAb |
A15734-100ul |
Abclonal |
100 ul |
EUR 369.6 |
TTC3 Rabbit pAb |
A15734-200ul |
Abclonal |
200 ul |
EUR 550.8 |
TTC3 Rabbit pAb |
A15734-20ul |
Abclonal |
20 ul |
EUR 219.6 |
TTC3 Rabbit pAb |
A15734-50ul |
Abclonal |
50 ul |
EUR 267.6 |
TTC5 rabbit pAb |
E44H12819 |
EnoGene |
100ul |
EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
TTC6 rabbit pAb |
E44H13310 |
EnoGene |
100ul |
EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
TTC3 Rabbit pAb |
MBS9142100-002mL |
MyBiosource |
0.02mL |
EUR 200 |
TTC3 Rabbit pAb |
MBS9142100-005mL |
MyBiosource |
0.05mL |
EUR 255 |
TTC3 Rabbit pAb |
MBS9142100-01mL |
MyBiosource |
0.1mL |
EUR 345 |
TTC3 Rabbit pAb |
MBS9142100-02mL |
MyBiosource |
0.2mL |
EUR 545 |
TTC3 Rabbit pAb |
MBS9142100-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2265 |
TTC3 Rabbit pAb |
MBS8550045-01mL |
MyBiosource |
0.1mL |
EUR 305 |
TTC3 Rabbit pAb |
MBS8550045-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
TTC3 Rabbit pAb |
MBS8550045-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
TTC3 Rabbit pAb |
MBS8550045-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
TTC3 Rabbit pAb |
MBS8550045-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
TTC1 Rabbit pAb |
A8745 |
Abclonal |
20μL |
EUR 262.15 |
TTC3 Rabbit pAb |
A21639 |
Abclonal |
20μL |
EUR 88.56 |
TTC8 Rabbit pAb |
A5129 |
Abclonal |
100μL |
EUR 262.15 |
TTC5 Rabbit pAb |
A13232 |
Abclonal |
1000μL |
EUR 262.15 |
TTC3 Rabbit pAb |
A15734 |
Abclonal |
1000μL |
EUR 262.15 |
TTC5 rabbit pAb |
UB-GEN-8611 |
UpingBio |
100 ul |
EUR 200 |
TTC6 rabbit pAb |
UB-GEN-9099 |
UpingBio |
100 ul |
EUR 200 |
Ttc39b (untagged ORF) - Rat tetratricopeptide repeat domain 39B (Ttc39b), (10 ug) |
RN214806 |
Origene Technologies GmbH |
10 µg |
Ask for price |
TTC9C rabbit pAb |
E28PN4682 |
EnoGene |
100μl |
EUR 255 |
Description: Available in various conjugation types. |
TTC9C rabbit pAb |
E44H13566 |
EnoGene |
100ul |
EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
TTC7A Rabbit pAb |
MBS9143747-002mL |
MyBiosource |
0.02mL |
EUR 200 |
TTC7A Rabbit pAb |
MBS9143747-005mL |
MyBiosource |
0.05mL |
EUR 255 |
TTC7A Rabbit pAb |
MBS9143747-01mL |
MyBiosource |
0.1mL |
EUR 345 |
TTC7A Rabbit pAb |
MBS9143747-02mL |
MyBiosource |
0.2mL |
EUR 545 |
TTC7A Rabbit pAb |
MBS9143747-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2265 |
TTC7A Rabbit pAb |
A20595 |
Abclonal |
20μL |
EUR 623.48 |
TTC9C rabbit pAb |
UB-GEN-9355 |
UpingBio |
100 ul |
EUR 200 |
TTC39B (NM_152574) Human Recombinant Protein |
PROTQ5VTQ0 |
BosterBio |
20ug |
EUR 1249 |
Description: Recombinant protein of human tetratricopeptide repeat domain 39B (TTC39B) |
TTC11 / FIS1 Rabbit pAb |
A5821-100ul |
Abclonal |
100 ul |
EUR 369.6 |
TTC11 / FIS1 Rabbit pAb |
A5821-200ul |
Abclonal |
200 ul |
EUR 550.8 |
TTC11 / FIS1 Rabbit pAb |
A5821-20ul |
Abclonal |
20 ul |
EUR 219.6 |
TTC11 / FIS1 Rabbit pAb |
A5821-50ul |
Abclonal |
50 ul |
EUR 267.6 |
TTC11/FIS1 Rabbit pAb |
MBS9145082-002mL |
MyBiosource |
0.02mL |
EUR 200 |
TTC11/FIS1 Rabbit pAb |
MBS9145082-005mL |
MyBiosource |
0.05mL |
EUR 255 |
TTC11/FIS1 Rabbit pAb |
MBS9145082-01mL |
MyBiosource |
0.1mL |
EUR 345 |
TTC11/FIS1 Rabbit pAb |
MBS9145082-02mL |
MyBiosource |
0.2mL |
EUR 545 |
TTC11/FIS1 Rabbit pAb |
MBS9145082-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2265 |
TTC11/FIS1 Rabbit pAb |
A5821 |
Abclonal |
50μL |
EUR 623.48 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (Azide free) (HRP) |
MBS6359951-02mL |
MyBiosource |
0.2mL |
EUR 980 |
TTC39B, CT (TTC39B, C9orf52, Tetratricopeptide repeat protein 39B) (Azide free) (HRP) |
MBS6359951-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
TTC23 (Center) Rabbit pAb |
E2613065 |
EnoGene |
100ul |
EUR 225 |
Description: Available in various conjugation types. |
TTC35 (Center) Rabbit pAb |
E2613869 |
EnoGene |
100ul |
EUR 225 |
Description: Available in various conjugation types. |
TTC23 (Center) Rabbit pAb |
MBS8552584-01mL |
MyBiosource |
0.1mL |
EUR 305 |
TTC23 (Center) Rabbit pAb |
MBS8552584-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
Macular structural characteristics on the limits and outside the lesions include intrarinal hyperreflective points, macular sistoid edema, subretinal fluid and loss of ellipsoid zone (EZ). Selective EZ losses found in 6 of 12 eyes showed recovery in 4 eyes after receiving anti-virus treatment. In the eye of CMVR, there are microvascular abnormalities and microstructure in the macular area without cmvr lesions that are clinically seen. Our results provide interesting insights into Retina CMV infection.